



## **Cumberland Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 16, 2010**

NASHVILLE, Tenn., July 28, 2010 /PRNewswire via COMTEX News Network/ -- **Cumberland Pharmaceuticals Inc.** (Nasdaq: CPIX) announced today that it will release second quarter 2010 financial results after the market closes on Monday, August 16, 2010. A conference call and live Internet webcast will be held on Monday, August 16, 2010 at 5:00 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers). The Conference ID for the rebroadcast is 90510603. The live webcast and rebroadcast can be accessed via Cumberland's website at <http://investor.shareholder.com/cpix/events.cfm>.

**Cumberland Pharmaceuticals Inc.** is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently launched Caldolor(R), the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

For more information on Cumberland Pharmaceuticals, please visit [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

Investor Contact:

Angela Novak  
Corporate Relations  
(615) 255-0068  
[anovak@cumberlandpharma.com](mailto:anovak@cumberlandpharma.com)

Media Contact:

Rebecca Kirkham  
Lovell Communications  
(615) 297-7766  
[rebecca@lovell.com](mailto:rebecca@lovell.com)

SOURCE Cumberland Pharmaceuticals Inc.

Copyright (C) 2010 PR Newswire. All rights reserved